RxDoctor Payments Data

Rachael Soles

Family · Moberly, MONPI 1467911149

Payments from drug & device makers

$1,208in general payments, 2019–2025

Across 23 payments — averaging $52.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$317
  • Abbott$258
  • AstraZeneca$109
  • Gilead$104
  • Lilly USA, LLC$102
  • Amgen$101
  • plus $218 from 4 others

What the payments were for

  • Food & beverage$1,208100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk12$317
Abbott2$258
AstraZeneca1$109
Gilead1$104
Lilly USA, LLC1$102
Amgen1$101
AbbVie2$95
GSK1$73
Dexcom, Inc.1$38
Merck1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,208 in reported general payments places this provider in the 70th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$890
Medicare patients
21
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide88$86,453
OzempicSemaglutide65$75,299
RexultiBrexpiprazole27$39,951
FarxigaDapagliflozin Propanediol39$31,605
EliquisApixaban24$19,926
Nurtec OdtRimegepant Sulfate12$12,057
LinzessLinaclotide18$11,895
JanuviaSitagliptin Phosphate16$11,260
SymbicortBudesonide/Formoterol Fumarate41$10,471
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,289
Spiriva RespimatTiotropium Bromide16$8,723
Combivent RespimatIpratropium/Albuterol Sulfate16$7,762
Janumet XrSitagliptin Phos/Metformin Hcl13$7,496
Albuterol Sulfate HfaAlbuterol Sulfate121$2,538
PremarinEstrogens, Conjugated12$2,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$102$86,45388 claims
Novo NordiskOzempic$317$75,29965 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$109$52,36596 claims
MerckJanuvia, Janumet Xr$13$18,75629 claims
AbbVieLinzess$95$11,89518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,812 family providers in Missouri.

Other family in Moberly

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →